[Form 4] VYNE Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reporting person David Domzalski, who serves as President and CEO and a Director, reported a transaction dated 09/30/2025. The filing shows 12,676 shares of common stock were disposed of under code F at a price of $0.335 per share; the form explains these shares were withheld by the issuer to satisfy tax withholding for vested restricted stock units. After the withholding, the reporting person beneficially owned 428,892 shares.

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/02/2025. No derivative transactions are reported on this form and no other transactions or compensatory changes are disclosed.

Positive

• Continued substantial ownership: reporting person retains 428,892 shares after the withholding
• Transaction was tax withholding (code F): indicates disposition was to satisfy tax on vested RSUs, not an open-market sale

Negative

• Shares disposed: 12,676 shares were withheld at $0.335 per share
• No derivatives disclosed: Form shows no new option exercises or derivative activity that might clarify other compensation changes

Insights

Corporate Governance & Insider Activity Analyst

TL;DR: CEO had 12,676 shares withheld for taxes on 09/30/2025, retaining 428,892 shares.

The filing records a tax-withholding disposition coded F, which the document explicitly states represents shares withheld to cover tax obligations from vested restricted stock units. This is a non-sale disposition method commonly used for executive equity compensation.

The reporting person continues to hold a substantial stake of 428,892 shares following the withholding. No options, warrants, or other derivative transactions are reported in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Domzalski David

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

685 ROUTE 202/206 N, SUITE 301

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F(1)		12,676	D	$0.335	428,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

	/s/ Mutya Harsch, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VYNE (VYNE) CEO David Domzalski report on Form 4?

He reported a disposition of 12,676 common shares on 09/30/2025 under code F, with 428,892 shares beneficially owned afterward.

Why were the 12,676 shares disposed of according to the filing?

The filing states the shares were withheld by the issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

What price is shown for the withheld shares?

The transaction lists a price of $0.335 per share for the 12,676 shares withheld.

Were any derivative securities reported on this Form 4 for VYNE?

No. The Form 4 contains no entries in Table II; only the non-derivative withholding is reported.

When was the Form 4 signed and by whom?

The form was signed by an attorney-in-fact, Mutya Harsch, on behalf of the reporting person on 10/02/2025.